SCHEMBL10147696

SCHEMBL10147696

COc1ccc2c(c1)c(CC(=O)NCCNC(=O)c1cc3ccccc3oc1=O)c(C)n2C=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.49
RXFP1 Q9HBX9 1/20 0.49
MAOB P27338 5/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 2/20 0.46
CA12 O43570 1/20 0.46
CA4 P22748 1/20 0.46
CA9 Q16790 1/20 0.46
POLB P06746 1/20 0.46
THRB P10828 1/20 0.46
MGAM O43451 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290297 0.85 CA12 (0.59) MAPTCA12CA4CA9
SCHEMBL837905 0.83 CA12 (0.68) CA12CA4CA9
SCHEMBL13290412 0.83 CA12 (0.55) MAPTCA12CA4CA9
SCHEMBL878348 0.83 PLA2G2A (0.46) NPC1RXFP1MAOBKDM4EALDH1A1
SCHEMBL10147607 0.82 CA12 (0.50) CA12CA4CA9
SCHEMBL14351090 0.82 CA12 (0.57) CA12CA4CA9
SCHEMBL878320 0.82 CA12 (0.58) CA12CA4CA9
SCHEMBL861472 0.81 PTGS2 (0.67) CA12CA4CA9
SCHEMBL13290395 0.79 PTGS2 (0.52)
SCHEMBL10147894 0.78 KDM4E (0.53) KDM4EALDH1A1MEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143302-B2 Methods and compositions for diagnostic and therapeutic targeting of COX-2 VANDERBILT UNIVERSITY (US) 2012-03-27 US disclosed
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 VANDERBILT UNIVERSITY (US) 2010-10-07 US disclosed
US-7736624-B2 derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy UNIV VANDERBILT (US) 2010-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 PTGS2, PTGES2, PTGER2 NPC1 1654/4885RXFP1 2356/4885MAOB 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.